Mimedx (MDXG) Current Assets (2010 - 2026)
Mimedx (MDXG) posted Current Assets of $205.4 million for Q2 2026, down 14.55% sequentially from $240.3 million in Q1 2026, and down 7.02% YoY from $220.9 million in Q2 2025.
Mimedx (MDXG) Current Assets (2010 - 2026) Analysis & Trends
Mimedx has reported Current Assets for 17 years, with the latest figure at $205.4 million in Q2 2026.
- Quarterly Current Assets fell 7.02% year-over-year to $205.4 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $205.4 million (down 7.02% YoY) and the FY2025 annual result came in at $277.5 million, up 44.6% from the prior year.
- Current Assets eased to $205.4 million in Q2 2026 per MDXG's latest filing, from $240.3 million in the prior quarter.
- Over five years, Current Assets peaked at $277.5 million in Q4 2025 and troughed at $131.0 million in Q2 2022.
- A 5-year average of $176.9 million and a median of $159.4 million in 2023 frame the typical range for Current Assets.
- The sharpest annual moves came in 2022 and 2025: Current Assets dropped 11.3% in 2022, then soared 47.61% in 2025.
- Over 5 years, Current Assets stood at $134.2 million in 2022, then advanced by 22.4% to $164.3 million in 2023, then increased by 16.82% to $191.9 million in 2024, then jumped by 44.6% to $277.5 million in 2025, then fell by 25.99% to $205.4 million in 2026.
- According to Business Quant data, Current Assets over the past three periods registered $205.4 million, $240.3 million, and $277.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Mimedx | 622.24 Mn | 486.40 Mn | 44.38 Mn | 205.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 205.37 Mn |
| Mar 31, 2026 | 240.33 Mn |
| Dec 31, 2025 | 277.47 Mn |
| Sep 30, 2025 | 254.10 Mn |
| Jun 30, 2025 | 220.88 Mn |
| Mar 31, 2025 | 200.11 Mn |
| Dec 31, 2024 | 191.89 Mn |
| Sep 30, 2024 | 172.14 Mn |
| Jun 30, 2024 | 154.02 Mn |
| Mar 31, 2024 | 138.85 Mn |
| Dec 31, 2023 | 164.26 Mn |
| Sep 30, 2023 | 154.50 Mn |
| Jun 30, 2023 | 141.22 Mn |
| Mar 31, 2023 | 131.70 Mn |
| Dec 31, 2022 | 134.20 Mn |
| Sep 30, 2022 | 136.04 Mn |
| Jun 30, 2022 | 131.01 Mn |
| Mar 31, 2022 | 135.91 Mn |
| Dec 31, 2021 | 148.52 Mn |
| Sep 30, 2021 | 141.90 Mn |